CME Information
Provider Statement: This continuing medical education activity is provided by 
.
Support Statement: This activity is supported by an educational grant from Genentech, Inc.
Target Audience: The intended audience for this activity is infectious disease specialists and other health care professionals involved in the treatment of patients with influenza.
Learning Objectives: Upon successful completion of this activity, participants should be better able to:
- Compare the efficacy and mechanisms of action of therapeutic agents in late-stage clinical trials to those currently available to prevent and treat influenza.
- Evaluate the latest clinical trial data regarding the therapeutic efficacy of agents in late stage development for the treatment of influenza.
- Assess the effects of emerging influenza treatments for their ability to reduce clinical illness, the duration of illness, viral shedding, and complications.
Activity Chair:
Frederick G. Hayden, MD, FACP, FIDSA
Professor Emeritus of Medicine
Stuart S. Richardson Professor Emeritus of Clinical Virology
University of Virginia School of Medicine
Charlottesville, VA
Faculty:
Aeron C. Hurt, PhD
Associate Professor
Senior Research Scientist, Head of Antiviral Susceptibility
WHO Collaborating Centre for Reference and Research on Influenza
Melbourne, Victoria
Michael G. Ison, MD, MS, FIDSA
Professor, Divisions of Infectious Diseases and Organ Transplantation
Northwestern University Feinberg School of Medicine
Chicago, IL
Nelson Lee, MD, MRCP(UK), FRCP(Lond), FIDSA
Professor, Division of Infectious Diseases
Department of Medicine
University of Alberta
Edmonton, Canada
Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Accreditation:
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation:
Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release November 12, 2018 to November 11, 2019.
How to Participate in This Activity and Obtain CME Credit:
To participate in this CME activity, you must read the objectives, answer the pretest questions, review the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.
The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.
Activity Chair and Faculty members report the following relationships:
Frederick G. Hayden, MD, FACP, FIDSA
Royalty: American Society for Microbiology
Consulting Fee: World Health Organization, University of Alabama Antiviral Discovery and Development Consortium (SAB)
Consulting Fee (donated directly to charities): Shionogi, Seqirus
Travel Support: Shionogi
Non-paid Consultant: Genentech/Roche, Janssen, Toyama/Fujifilm, Vir, Visterra
Data Safety & Monitoring Board (paid to institution): Celltrion, GlaxoSmithKlein, Vaccitech
Aeron C. Hurt, PhD
Contracted Research (paid to institution): AusBio, Romark, Shionogi
Michael G. Ison, MD, MS, FIDSA, FAST
Royalty: UpToDate
Consulting Fee: Celltrion, Genentech/Roche, Janssen, Seqirus, Shionogi, Toyama/MediVector, VirBio
Contracted Research: Beckman Coulter, Cepheid, Chimerix, Emergent BioScience, Gilead, Janssen, Shire
Data Safety & Monitoring Board Membership: GlaxoSmithKline, Shionogi
Nelson Lee, MD, MRCP(UK), FRCP(Lond), FIDSA
Consulting Fee: Janssen, Seqirus, Shionogi
Travel Support: Janssen, Seqirus, Shionogi
Reviewers report the following relationship(s):
Ronald A. Codario MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationship to disclose.
Vindico Medical Education staff report the following relationship(s):
No relevant financial relationship to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
Copyright Statement:
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2018 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at cme@vindicoCME.com